Clinical Trial Update: Nivo/Ipi Combination Therapy in Symptomatic Brain Metastases [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating the nivolumab and ipilimumab combination in symptomatic melanoma with brain metastases has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Metastases
• Melanoma

Drugs mentioned

• OPDIVO (nivolumab)
• Yervoy (ipilimumab)

Snippet

Sponsor: University Medical Center Groningen | Conditions: Melanoma, Brain Metastasis | Phase 2 | Status: TERMINATED